<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/340AFC6A-4E6F-467A-B184-E775A92259B4"><gtr:id>340AFC6A-4E6F-467A-B184-E775A92259B4</gtr:id><gtr:firstName>Juan</gtr:firstName><gtr:surname>Martin-Serrano</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400207"><gtr:id>DAB3252F-194C-479D-9F61-221C3C2EBD3F</gtr:id><gtr:title>Role of ESCRT-I and ESCRT-II in HIV-I budding</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400207</gtr:grantReference><gtr:abstractText>The last step in retroviral life cycle is the separation of the nascent viral particle from the infected cell. HIV-1 and other retroviruses encode a so-called Late Budding domain (L-domain) whose mutation induces the accumulation of immature virions that remain tethered to the plasma membrane by a membranous stalk. Recent work by our group and other laboratories has identified the cellular protein Tsg101 as the cellular partner that facilitates HIV-1 and Ebola virus budding thorough the interaction with a highly conserved aminoacid motif (PTAP) in the L-domain of these pathogens. In subsequent work a group of cellular proteins that participate in budding of highly divergent enveloped viruses has also been identified. We and others have recently constructed a protein-protein interaction map that connects Tsg101 with the cellular machinery that is believed to facilitate viral budding, but the functional importance of many of these interactions needs to be determined. The main goal of this project is to elucidate the molecular events that mediate the recruitment of the cellular budding/fusion machinery by Tsg101 during HIV-1 particle assembly. This aim will be studied by determining the role in HIV-1 budding of known proteins that interact with Tsg101 (VPS28, EAP20, EAP30 and EAP45) and by identifying and studying the function of novel Tsg101 interacting proteins. Finally, we propose two different approaches to determine whether the PTAP/Tsg101 is a valid therapeutic target for AIDS treatment. Importantly, a greater understanding of how HIV-1 viruses exploit the host cell to facilitate the budding process could provide opportunities for chemotherapeutic intervention using a completely novel class of antiviral compounds that would be active against a number of human pathogens including HIV-1, HIV-2, Ebola virus, HTLV, Lassa fever virus and essentially any virus that exploits the PTAP/Tsg101 interaction during budding.</gtr:abstractText><gtr:technicalSummary>The last step in retroviral life cycle is the separation of the nascent viral particle from the infected cell. HIV-1 and other retroviruses encode a so-called Late Budding domain (L-domain) whose mutation induces the accumulation of immature virions that remain tethered to the plasma membrane by a membranous stalk. Work by our group and other laboratories has identified the cellular protein Tsg101 as the cellular partner that facilitates HIV-1 and Ebola virus budding thorough the interaction with a highly conserved aminoacid motif (PTAP) in the L-domain of these pathogens. Subsequently, it has been shown that other viruses that include HIV-2, HTLV and Lassa fever virus also require Tsg101 for particle budding, thus emphasizing the importance of this protein in human disease. Tsg101, the mammalian orthologue of the yeast protein Vps23, is one of the subunits of a 350 kd complex (endosomal sorting complex required for transport-I, ESCRT-I) which also includes Vps28 and Vps37. The human orthologues of Vps23 and Vps28 have been described whereas the orthologue of Vps37 has not yet been identified. Tsg101 is a component of the class E pathway and is required both for the budding of viruses that encode PTAP type L-domains and the topologically equivalent process of vesicle budding into Multivesicular Bodies (MVB). Recent work by our laboratory and others has identified 19 human components of the class E pathway that participate in budding of highly divergent enveloped viruses and, perhaps, MVB biogenesis. The protein-protein interaction map of the human class E proteins describe interactions that connect Tsg101 with ESCRT-III, the cellular machinery that is believed to mediate membrane fusion, but the functional importance of many of these interactions needs to be determined. The main goal of this project is to elucidate the molecular events that mediate the recruitment of the cellular budding/fusion machinery by Tsg101 during HIV-1 particle assembly. We propose a detailed study of VPS28, an ESCRT-I component, and screening experiments to identify and determine the role in HIV-1 budding of the human orthologue of Vps37 and other novel Tsg101 interacting proteins. Based on the fact that the ESCRT-II complex interacts both with Tsg101 and the ESCRT-III machinery, we propose studies to elucidate the role in viral budding of the three ESCRT-II subunits, EAP20, EAP30 and EAP45. Finally, we propose two different genetic approaches to determine whether the PTAP/Tsg101 is a valid therapeutic target for AIDS treatment.</gtr:technicalSummary><gtr:fund><gtr:end>2010-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>653913</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>39000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EMBO Young Investigator Programme</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>European Molecular Biology Organisation (EMBO)</gtr:fundingOrg><gtr:id>ADB67F33-3F41-4E19-8247-752937DE66C1</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140078</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome-Beit Prize Fellowships</gtr:department><gtr:description>Beit Memorial Fellowships for Medical Research</gtr:description><gtr:end>2009-02-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>0C61472E-6C15-444E-9986-98D84A4359AC</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2006-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>967648</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant G0802777</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0EC68BB4-BAA2-45F4-B7FF-226D0867A4CB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>259231</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (Uncovering the role of MITD1 in ESCRT function)</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>WT093056</gtr:fundingRef><gtr:id>5C1431E7-D275-4160-AC11-240E50F11B47</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lister Research Prize Fellowship (Functional parallels between HIV-1 budding and the last step of cell division)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Lister Institute of Preventive Medicine</gtr:fundingOrg><gtr:id>B3367EBC-8B70-4B6A-B08C-E70AADAD9189</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>These are stable cell lines expressing a fluorescent versions of several components of the ESCRT machinery and other interacting proteins</gtr:description><gtr:id>6F0835F3-5E62-4EE5-8C5E-DE7D60C49CB8</gtr:id><gtr:impact>These cell lines have been shared with several researchers that are investigating the role of cellular proteins in HIV-1 replication and cytokinesis.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Hela YFP-Tsg101, Hela Cherry-Cep55, Hela YFP-ALIX</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Our laboratory has created many plasmids encoding fusions of the ESCRT subunits to various tags, such as fluorescent proteins, GST, yeast two hybrid, etc</gtr:description><gtr:id>2E6531DF-EA97-4D18-B8E3-19DAB2312C37</gtr:id><gtr:impact>We constantly share these plasmids on request with many research groups that work in several areas of research, such as virology and cell biology</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Plasmids encoding several variations of the ESCRT subunits</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Our laboratory has created many plasmids encoding fusions of the ESCRT subunits to various tags, such as fluorescent proteins, GST, yeast two hybrid, etc</gtr:description><gtr:id>828FCD4E-8958-4976-90B6-46696D57A692</gtr:id><gtr:impact>We constantly share these plasmids on request with many research groups that work in several areas of research, such as virology and cell biology</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Plasmids encoding several variations of the ESCRT subunits</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BDF404C4-0433-4B38-A857-848BBC407D82"><gtr:id>BDF404C4-0433-4B38-A857-848BBC407D82</gtr:id><gtr:title>Differential requirements for Alix and ESCRT-III in cytokinesis and HIV-1 release.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43118aa955965c0754d2fec188730444"><gtr:id>43118aa955965c0754d2fec188730444</gtr:id><gtr:otherNames>Carlton JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9D3AE9AA-156B-43CA-9B1C-D104638D7D00"><gtr:id>9D3AE9AA-156B-43CA-9B1C-D104638D7D00</gtr:id><gtr:title>The ESCRT machinery: new functions in viral and cellular biology.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43118aa955965c0754d2fec188730444"><gtr:id>43118aa955965c0754d2fec188730444</gtr:id><gtr:otherNames>Carlton JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/199E6556-6071-4820-A20D-C55ED8F4DDE3"><gtr:id>199E6556-6071-4820-A20D-C55ED8F4DDE3</gtr:id><gtr:title>Parallels between cytokinesis and retroviral budding: a role for the ESCRT machinery.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43118aa955965c0754d2fec188730444"><gtr:id>43118aa955965c0754d2fec188730444</gtr:id><gtr:otherNames>Carlton JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF590F70-3176-4E1A-93F6-072CDD6AB750"><gtr:id>DF590F70-3176-4E1A-93F6-072CDD6AB750</gtr:id><gtr:title>ALIX catches HIV.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/394e175a960f6fd2f11dd2eb059ea9ef"><gtr:id>394e175a960f6fd2f11dd2eb059ea9ef</gtr:id><gtr:otherNames>Martin-Serrano J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5CD62EB2-9C98-452E-8076-5313546E5982"><gtr:id>5CD62EB2-9C98-452E-8076-5313546E5982</gtr:id><gtr:title>The role of ubiquitin in retroviral egress.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/394e175a960f6fd2f11dd2eb059ea9ef"><gtr:id>394e175a960f6fd2f11dd2eb059ea9ef</gtr:id><gtr:otherNames>Martin-Serrano J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/027E1F8D-1430-4339-AF53-A67DB84B3144"><gtr:id>027E1F8D-1430-4339-AF53-A67DB84B3144</gtr:id><gtr:title>Interaction of AMSH with ESCRT-III and deubiquitination of endosomal cargo.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ccc6e00645d6982afab2e48beee2007f"><gtr:id>ccc6e00645d6982afab2e48beee2007f</gtr:id><gtr:otherNames>Agromayor M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0C5142AB-6B25-441F-B2D9-43BBE8BF9984"><gtr:id>0C5142AB-6B25-441F-B2D9-43BBE8BF9984</gtr:id><gtr:title>Essential role of hIST1 in cytokinesis.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ccc6e00645d6982afab2e48beee2007f"><gtr:id>ccc6e00645d6982afab2e48beee2007f</gtr:id><gtr:otherNames>Agromayor M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B9B7EA81-7A3F-4C88-B039-2C3DE00DAB6D"><gtr:id>B9B7EA81-7A3F-4C88-B039-2C3DE00DAB6D</gtr:id><gtr:title>Regulation of Tsg101 expression by the steadiness box: a role of Tsg101-associated ligase.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e61415fec4ee8ff7b278aae5f3cd38e7"><gtr:id>e61415fec4ee8ff7b278aae5f3cd38e7</gtr:id><gtr:otherNames>McDonald B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/48CD0120-1E5E-492B-94FC-BB2B10464A6E"><gtr:id>48CD0120-1E5E-492B-94FC-BB2B10464A6E</gtr:id><gtr:title>No strings attached: the ESCRT machinery in viral budding and cytokinesis.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e61415fec4ee8ff7b278aae5f3cd38e7"><gtr:id>e61415fec4ee8ff7b278aae5f3cd38e7</gtr:id><gtr:otherNames>McDonald B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400207</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>